Barbee, M. S., Ogunniyi, A., Horvat, T., & Dang, T. (2015). Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembroluzimab, and nivolumab in oncology. Annals of Pharmacotherapy,… Click to show full abstract
Barbee, M. S., Ogunniyi, A., Horvat, T., & Dang, T. (2015). Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembroluzimab, and nivolumab in oncology. Annals of Pharmacotherapy, 49(8), 907–937. Bristol-Myers Squibb Company. (2014). Opdivo R © (nivolumab): Highlights of prescribing information. Princeton, NJ: Author. Bristol-Myers Squibb Company. (2015). Yervoy R © (ipilimumab): Highlights of prescribing information. Princeton, NJ: Author. Chae, Y. K., Chiec, L., Mohinra, N., Gentzler, R., Patel, J., & Giles, F. (2017). A case of pembrolizumab-induced Type 1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced Type 1 diabetes. Cancer Immunology, Immunotherapy: CII, 66(1), 25–32. Gaudy, C., Clevy, C., Monestier, S., Dubois, N., Preau, Y., Mallet, S., . . . Beliard, S. (2015). Anti-PD1 pembrolizumab can induce exceptional fulminant Type 1 diabetes. Diabetes Care, 38, e182–e183. Hansen, E., Sahasrabudhe, D., & Sievert, L. (2016). A case report of insulin-dependent diabetes as immunerelated toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunology, Immunotherapy, 65, 765–767. Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., . . . Heinzerling, L. M. (2016). Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 60, 190–209. Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., & Herold, K. (2015). Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care, 38, e55–e57. Martin-Liberal, J., Furness, A., Joshi, K., Peggs, K. S., Quezada, S. A., & Larkin, J. (2015). Anti-programmed cell death-1 therapy and insulin-dependent diabetes: A case report. Cancer Immunology, Immunotherapy: CII, 64, 765–767. Mellati, M., Eaton, K. D., Brooks-Worrell, B. M., Hagopian, W. A., Martins, R., Palmer, J. P., & Hirsch, I. B. (2015). Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing Type 1 diabetes. Diabetes Care, 38, e137–e138. Merck & Company, Inc. (2014). Kaytruda R © (pembrolizumab): Highlights of prescribing information. Whitehouse Station, NJ: Author. Miyoshi, Y., Ogawa, O., & Oyama, Y. (2016). Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant Type 1 diabetes. Tohoku Journal of Experimental Medicine, 239, 155–158. Munakata, W., Ohashi, K., Yamauchi, N., & Tobinai, K. (2017). Fulminant Type 1 diabetes associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. International Journal of Hematology, 105(3), 383–386. Okamoto, M., Okamoto, M., Gotoh, K., Takayuki, M., Yoshinori, O., Hisae, A., . . . Hirotaka, S. (2016). Fulminant Type 1 diabetes mellitus with antiprogrammed cell death-1 therapy. Journal of Diabetes Investigation, 7, 915–918. Teramoto, Y., Nakamura, Y., Asami, Y., Imamura, T., Takahira, S., Nemoto, M., . . . Yamamoto, A. (2016). Case of Type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. Journal of Dermatology, 44, 605–606.
               
Click one of the above tabs to view related content.